Gilead profit meets Wall St forecast, sales rise 14 pct
July 25 (Reuters) - Gilead Sciences Inc on Thursday said its quarterly profit rose nearly 9 percent, in line with Wall Street estimates, as sales, including of its flagship HIV drugs, increased 14 percent.
The world's largest maker of branded HIV drugs said second-quarter net profit rose to $772.6 million, or 46 cents per share, from $711.6 million, or 46 cents per share, a year earlier.
Excluding items, Gilead earned 50 cents a share in the quarter, matching the average analyst estimate, as compiled by Thomson Reuters I/B/E/S.
Sales of HIV drug Atripla rose 4 percent to $938.1 million, while sales of an older product, Truvada, rose 3 percent to $807.8 million. Sales of newer HIV drug Complera more than doubled to $188.7 million, and recently launched Stribild had sales of $99.4 million for the quarter.
Revenue for the quarter rose 15 percent to $2.77 billion, outpacing the average analyst estimate of $2.66 billion.
- Exclusive: Radar data suggests missing Malaysia plane deliberately flown way off course - sources
- Investigators focus on foul play behind missing plane: sources |
- CEOs of biggest Russian firms could be hit by sanctions: paper |
- Kremlin website hit by 'powerful' cyber attack
- Search for Malaysian plane may extend to Indian Ocean - U.S |